Antengene Corporation Limited (SEHK: 6996.HK), a leading innovative commercial-stage global biotech company focused on autoimmune diseases, solid tumors, and hematological malignancies, has entered into a pivotal clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (SEHK: 1877.HK; SSE: 688180). This partnership aims to jointly assess the synergistic therapeutic potential of Antengene's ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi's JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody. The study targets patients with solid tumors in Mainland China, seeking to identify clinical signals across multiple tumor types.

This collaboration is grounded in promising Phase I proof-of-concept data for ATG-037, particularly its ability to reverse resistance to checkpoint inhibitors (CPIs), a major challenge in current immunotherapies. By combining ATG-037's mechanism of alleviating adenosine-mediated immunosuppression with JS207's dual inhibition of PD-1 and VEGF pathways, the duo employs a 'triple-axis' approach: immune checkpoint signaling, anti-angiogenesis, and enhanced immune response. This strategy holds potential to improve efficacy of existing treatments and extend overall survival (OS) for cancer patients.

JS207 has shown robust monotherapy efficacy, as presented in a poster at ESMO Asia 2025. In 62 patients with PD-L1 positive non-small cell lung cancer (NSCLC) receiving JS207 as first-line treatment, it achieved an objective response rate (ORR) of 58.1% and a disease control rate (DCR) of 87.1%. These results underscore JS207's promise in solid tumors. Furthermore, the U.S. FDA has approved the investigational new drug (IND) application for JS207, enabling an open-label, two-arm, randomized, active-controlled Phase II/III study comparing it to nivolumab for neoadjuvant treatment in stage II/III resectable NSCLC patients without actionable genomic aberrations.

For Antengene, this partnership accelerates the clinical evaluation of ATG-037 across multiple solid tumor indications. Antengene's robust pipeline includes in-house discoveries like ATG-022 (CLDN18.2 ADC), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). The company has secured 32 IND approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia-Pacific markets. Its lead asset, XPOVIO® (selinexor), is approved in Mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, Indonesia, and Australia, with inclusion in national insurance schemes in five markets.

This collaboration exemplifies the growing trend of strategic partnerships in Asia's biotech sector, leveraging complementary expertise in target biology and clinical development. Both companies anticipate rapid progress in identifying synergistic effects, potentially transforming treatment paradigms for solid tumors. Antengene's investor contact is Donald Lung ([email protected]), and business development contact is Ariel Guo ([email protected]). The agreement highlights Shanghai and Hong Kong's roles as biotech hubs, fostering innovation in oncology through contract research and development collaborations.

In the broader context of pharmaceutical outsourcing and contract services, such alliances are critical for CRO/CMO leaders navigating Asia's regulatory landscape. The focus on combination therapies addresses unmet needs in immuno-oncology, aligning with categories like biotechnology, contract clinical trials, and pharmaceutical formulations. As global pharma seeks Asian pipelines, this deal positions both firms for future licensing and commercialization opportunities, enhancing supply chain solutions for advanced therapeutics.

The initiative also reflects economic and regional development in China's biotech ecosystem, where innovative drug pipelines are expanding rapidly. By targeting CPI resistance, the collaboration could set precedents for future multi-asset studies, benefiting R&D heads and manufacturing managers in scaling production of bispecific antibodies and small-molecule inhibitors. Procurement professionals should note the potential for new active pharmaceutical ingredients (APIs) and intermediates emerging from these trials.

Overall, this partnership underscores the strategic importance of Asian B2B pharma collaborations in driving next-generation therapies, with implications for laboratory services, validation processes, and quality assurance in clinical development.